Cargando…

Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study

Various types of botulinum toxin (BoNT) have been studied to treat cervical dystonia (CD). Although high-dose BoNT has proven efficacy, it increases the risk of adverse events. For this reason, this study was planned to identify the non-inferiority efficacy, tolerability, and safety of low-dose neub...

Descripción completa

Detalles Bibliográficos
Autores principales: Kongsaengdao, Subsai, Arayawithchanont, Arkhom, Samintharapanya, Kanoksri, Rojanapitayakorn, Pichai, Maneeton, Benchalak, Maneeton, Narong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541224/
https://www.ncbi.nlm.nih.gov/pubmed/34678987
http://dx.doi.org/10.3390/toxins13100694
_version_ 1784589178011385856
author Kongsaengdao, Subsai
Arayawithchanont, Arkhom
Samintharapanya, Kanoksri
Rojanapitayakorn, Pichai
Maneeton, Benchalak
Maneeton, Narong
author_facet Kongsaengdao, Subsai
Arayawithchanont, Arkhom
Samintharapanya, Kanoksri
Rojanapitayakorn, Pichai
Maneeton, Benchalak
Maneeton, Narong
author_sort Kongsaengdao, Subsai
collection PubMed
description Various types of botulinum toxin (BoNT) have been studied to treat cervical dystonia (CD). Although high-dose BoNT has proven efficacy, it increases the risk of adverse events. For this reason, this study was planned to identify the non-inferiority efficacy, tolerability, and safety of low-dose neubotulinum toxin A (Neu-BoNT-A) versus low-dose abobotulinum toxin A (Abo-BoNT-A) in CD treatment. The 48-week, prospective, randomized, controlled crossover design study of CD treatment, with 50-unit Neu-BoNT-A and 250-unit Abo-BoNT-A injections at 12-week intervals, was conducted over a 24-week treatment period. This study used the following standardized rating scales to assess the efficacy of BoNT: the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS); health-related quality of life (HRQoL); the Cervical Dystonia Impact Profile (CDIP-58); the Short Form 36 health survey questionnaire (SF-36); and, for the depressive symptoms of CD patients, the Center for Epidemiological Studies-Depression Scale (CES-D) and the Patient Health Questionnaire-9 (PHQ-9). Fifty-two CD patients were enrolled from October 2019 to January 2021. The mean scores of the TWSTRS total at the post-treatments in both Neu-BoNT-A and Abo-BoNT-A had a significant reduction from baseline (p = 0.008 and 0.002, respectively). However, the mean changes of the TWSTRS total at the 12- and 24-week treatments between the two treatment groups were not significantly different (p = 0.284 and 0.129, respectively). The mean scores of the HRQoL questionnaires (the CIDP-58 and the SF-36) and the depressive symptoms (the CES-D and the PHQ-9) in both treated groups at the post-treatments did not significantly decrease from baseline and were comparable. Two patients treated with Abo-BoNT-A (250 units) reported cervical tension and benign paroxysmal positional vertigo (BPPV). There were no serious adverse events reported. Though both low-dose BoNT-As were effective at improving clinical symptoms without significant side effects, both treatments did not predict change in quality of life and depression. With the non-inferiority criteria, low-dose Neu-BoNT-A has a similar efficacy, safety, and tolerability to Abo-BoNT-A.
format Online
Article
Text
id pubmed-8541224
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85412242021-10-24 Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study Kongsaengdao, Subsai Arayawithchanont, Arkhom Samintharapanya, Kanoksri Rojanapitayakorn, Pichai Maneeton, Benchalak Maneeton, Narong Toxins (Basel) Article Various types of botulinum toxin (BoNT) have been studied to treat cervical dystonia (CD). Although high-dose BoNT has proven efficacy, it increases the risk of adverse events. For this reason, this study was planned to identify the non-inferiority efficacy, tolerability, and safety of low-dose neubotulinum toxin A (Neu-BoNT-A) versus low-dose abobotulinum toxin A (Abo-BoNT-A) in CD treatment. The 48-week, prospective, randomized, controlled crossover design study of CD treatment, with 50-unit Neu-BoNT-A and 250-unit Abo-BoNT-A injections at 12-week intervals, was conducted over a 24-week treatment period. This study used the following standardized rating scales to assess the efficacy of BoNT: the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS); health-related quality of life (HRQoL); the Cervical Dystonia Impact Profile (CDIP-58); the Short Form 36 health survey questionnaire (SF-36); and, for the depressive symptoms of CD patients, the Center for Epidemiological Studies-Depression Scale (CES-D) and the Patient Health Questionnaire-9 (PHQ-9). Fifty-two CD patients were enrolled from October 2019 to January 2021. The mean scores of the TWSTRS total at the post-treatments in both Neu-BoNT-A and Abo-BoNT-A had a significant reduction from baseline (p = 0.008 and 0.002, respectively). However, the mean changes of the TWSTRS total at the 12- and 24-week treatments between the two treatment groups were not significantly different (p = 0.284 and 0.129, respectively). The mean scores of the HRQoL questionnaires (the CIDP-58 and the SF-36) and the depressive symptoms (the CES-D and the PHQ-9) in both treated groups at the post-treatments did not significantly decrease from baseline and were comparable. Two patients treated with Abo-BoNT-A (250 units) reported cervical tension and benign paroxysmal positional vertigo (BPPV). There were no serious adverse events reported. Though both low-dose BoNT-As were effective at improving clinical symptoms without significant side effects, both treatments did not predict change in quality of life and depression. With the non-inferiority criteria, low-dose Neu-BoNT-A has a similar efficacy, safety, and tolerability to Abo-BoNT-A. MDPI 2021-10-01 /pmc/articles/PMC8541224/ /pubmed/34678987 http://dx.doi.org/10.3390/toxins13100694 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kongsaengdao, Subsai
Arayawithchanont, Arkhom
Samintharapanya, Kanoksri
Rojanapitayakorn, Pichai
Maneeton, Benchalak
Maneeton, Narong
Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study
title Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study
title_full Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study
title_fullStr Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study
title_full_unstemmed Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study
title_short Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study
title_sort low-dose neubotulinum toxin a versus low-dose abobotulinum toxin a injection for the treatment of cervical dystonia: a multicenter, 48-week, prospective, double-blinded, randomized crossover design study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541224/
https://www.ncbi.nlm.nih.gov/pubmed/34678987
http://dx.doi.org/10.3390/toxins13100694
work_keys_str_mv AT kongsaengdaosubsai lowdoseneubotulinumtoxinaversuslowdoseabobotulinumtoxinainjectionforthetreatmentofcervicaldystoniaamulticenter48weekprospectivedoubleblindedrandomizedcrossoverdesignstudy
AT arayawithchanontarkhom lowdoseneubotulinumtoxinaversuslowdoseabobotulinumtoxinainjectionforthetreatmentofcervicaldystoniaamulticenter48weekprospectivedoubleblindedrandomizedcrossoverdesignstudy
AT samintharapanyakanoksri lowdoseneubotulinumtoxinaversuslowdoseabobotulinumtoxinainjectionforthetreatmentofcervicaldystoniaamulticenter48weekprospectivedoubleblindedrandomizedcrossoverdesignstudy
AT rojanapitayakornpichai lowdoseneubotulinumtoxinaversuslowdoseabobotulinumtoxinainjectionforthetreatmentofcervicaldystoniaamulticenter48weekprospectivedoubleblindedrandomizedcrossoverdesignstudy
AT maneetonbenchalak lowdoseneubotulinumtoxinaversuslowdoseabobotulinumtoxinainjectionforthetreatmentofcervicaldystoniaamulticenter48weekprospectivedoubleblindedrandomizedcrossoverdesignstudy
AT maneetonnarong lowdoseneubotulinumtoxinaversuslowdoseabobotulinumtoxinainjectionforthetreatmentofcervicaldystoniaamulticenter48weekprospectivedoubleblindedrandomizedcrossoverdesignstudy